Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 4/17/2018 |
| Start Date: | July 13, 2017 |
| End Date: | March 4, 2018 |
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of BMS- 986177 in Participants With Normal Renal Function and Participants With Moderate and Severe Renal Impairment
Assess the pharmacokinetics, safety, and tolerability of a single dose of BMS-986177 in
participants with normal renal function and moderate to severe renal impairment.
participants with normal renal function and moderate to severe renal impairment.
Inclusion Criteria:
- Participants in Groups B and C will be classified by renal function by eGRF at
screening and confirmed on Day -1
- Participants in Group A will be healthy participants as determined by no significant
deviations in normal medical and surgical history and assessments
- Participants in Group A must have a body mass index of 18.0 to 32.0 kg/m2, inclusive
- Females must be of non-childbearing potential
Exclusion Criteria:
- Participants in Groups B and C cannot have an indwelling catheter for hemodialysis
- Participants in Groups B and C cannot have had, nor be waiting for, an organ
transplant
Other protocol defined inclusion and exclusion criteria could apply
We found this trial at
1
site
Click here to add this to my saved trials
